What is MMT?
Veterinary expert-developed Breakthrough
Natural Therapeutics for Intractable Pet Diseases
The Growing Challenge of Intractable Diseases in Pets
Pets are no longer just pets—they are family.
They share our lives and routines, becoming deeply connected members of our households. As veterinary care advances, pets are living longer, but this increased lifespan has also led to a rise in chronic and intractable diseases.
On average, pets live about 12 years, and nearly the last 25% of their lives—approximately three years—are often spent struggling with severe, hard-to-treat conditions. These prolonged illnesses significantly reduce quality of life and place emotional strain on pet families, highlighting the need for a more fundamental, root-cause–focused approach to pet healthcare.
3 Major Limitations of Current Pet Treatments
Optimal pet health
It can only be achieved when the ‘Gut-Immune-Kidney’ (Tri-Axes) are closely interconnected and maintain systemic homeostasis.
❌ Single-Target Therapy
Accumulation of internal toxins
Dysbiosis of the gut/ immune system
Collapse of the Tri-Axes interaction
Reduced therapeutic efficacy and increased complications
Revolutionary Multi-Mechanism Therapeutics (MMT)
Multi-Mechanism Therapeutics (MMT)
Removal of accumulated toxic metabolites
Resolution of gut/immune system imbalance
Simultaneous restoration of the three core axes (Tri-Axes) interaction
Amplified therapeutic efficacy and minimized risk of complications
MMT fundamentally treats intractable diseases, thereby improving pets’ longevity and overall quality of life (QoL)
Bundle of PETMUNIOME & KIDNIOME (Tri-Axes Solution)
Exclusively available at K-Herbal,
delivering integrated Tri-Axes care for pets
1.PETMUNIOME
Restores Immune Function
2. KIDNIOME
Preserves Kidney Function
- Natural formulations : Mechanism of action based on SCI-level papers of key ingredients.
- Key Ingredients : Dendropanax morbiferus, Saururus chinensis Baill, Rehmannia glutinosa, Cornus officinalis, Etc.
Bundle of PETMUNIOME & KIDNIOME (Tri-Axes Solution)
1.PETMUNIOME – Target : 4 end-stage Cancer Dogs
Average Improvement in 11 key biomarkers : 28.9% (led by LY (Lymphocyte) 48.2% / CRP 21.3%)Average Weight Gained at 2.8% Up- KIDNIOME – Target: : 4 end-stage Kidney Failure Cats
Average Improvement in 11 key biomarkers : 19.9% (led by Creatinine 27.6% / Ammonia 46.3%)Average Weight Maintained at -1.7% Down